4D Molecular Therapeutics Hits New 52-Week High at $14.00

4D Molecular Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 14.00 on June 30, 2026. This achievement marks a notable recovery from its 52-week low of USD 3.68, showcasing a substantial upward movement in the stock's performance. Despite this recent high, the company's one-year performance reflects a decline of 41.07%, contrasting sharply with the S&P 500's gain of 20.86% over the same period. The market capitalization of 4D Molecular Therapeutics stands at USD 476 million, indicating its position within the microcap segment of the market. Financial metrics reveal that the company is currently loss-making, with a negative return on equity of -27.72% and a debt-to-equity ratio of -0.79. The price-to-book ratio is recorded at 0.94, suggesting that the stock may be trading below its book value. As 4D Molecular Therapeutics continues to navigate the complexities of the biotechnology landscape, this new high underscores a pivotal moment in its market journey.